« Return to News | R&D Trends

Spinifex receives $1.5M in R&D tax incentive relating to pain research

Wednesday, March 27, 2013 09:28 AM

Spinifex Pharmaceuticals, an Australian pain drug development company, has received an approximately $1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain.

The R&D Incentive Program is an annual program, jointly administered by AusIndustry and the Australian Taxation Office, which enables Spinifex to apply for it in subsequent years. Spinifex will reinvest the funds in further clinical development of its lead candidate, EMA401, an AT2 receptor antagonist for the treatment of chronic pain, including neuropathic pain.

Spinifex reported positive results of its phase II study of EMA401 in post-herpetic neuralgia (PHN) in the third quarter of 2012, and more recently initiated a phase II proof-of-concept study in chemotherapy-induced peripheral neuropathy (CIPN).

"This payment under the R&D tax incentive program is a good example of how government initiatives can support innovative companies in the biotechnology industry and other sectors,” said Tom McCarthy, CEO of Spinifex Pharmaceuticals. “These additional funds are welcome and we look forward to their contributing to our continued clinical development of EMA401 for the treatment of chronic and neuropathic pain indications. In addition to this payment, we continue to expand our non-clinical activities with the support of our existing investors."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.